Company:  CELGENE CORP /DE/ (CELG)
Form Type:  8-K
Filing Date:  1/9/2012 
CIK:  0000816284 
Address:  86 MORRIS AVENUE 
City, State, Zip:  SUMMIT, New Jersey 07901 
Telephone:  (908)673-9000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$87.52  
Change: 
1.80 (2.10%)  
Trade Time: 
Jul 09  
Market Cap: 
$70.09B
Description of Business
Celgene Corporation, together with its subsidiaries (collectively �we,� �our,� �us,� �Celgene� or the �Company�), is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated to innovative research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. Celgene Corporation was incorporated in the State of Delaware in 1986.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1
BROKERAGE PARTNERS